Feb 18, 2022 / 01:30AM GMT
Tim McGowen - ShareCafe - Analyst
I'm ready to start. First up we have Genetic Signatures, ISX code GSS, market cap of around $192 million, one-year return of minus 22%. The company is a specialist molecular diagnostics company focused on the development and commercialization of its proprietary platform technology, 3base. We have and welcome back CEO and Director, John Melki. John, over to you. Thank you.
John Melki - Genetic Signatures Ltd. - CEO & Director
Thanks so much, Tim. It's always a pleasure to be part of ShareCafe. I'm going to use the next 10 minutes to introduce the Company to those that don't know us. I'm going to highlight our half year financial results, which we just released this morning, and I'm going to discuss our plans looking forward, particularly in that post COVID era.
So if I can go through to my first slide. So Genetic Signatures is a 20-year-old listed company. We make molecular or PCR based tests to identify infectious diseases. So these are the microorganisms that infect humans, they make us sick. Some of them have a
Genetic Signatures Ltd Participates at ShareCafe Small Cap Hidden Gems Webinar Transcript
Feb 18, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers